Table 2.
Recipient characteristics n (%)
| Recipient variables | n = 28 |
| Transplant center (No. of patients) | |
| Modena | 6 (21.4) |
| Bologna | 16 (57.1) |
| Padova | 6 (21.4) |
| Gender | |
| Male | 24 (85.7) |
| Female | 4 (14.3) |
| AB0 blood group | |
| Isogroup | 28 (100) |
| 0 | 7 (25) |
| A | 17 (60.7) |
| B | 4 (14.3) |
| Age (yr), mean (range, SD) | 57.6 (26-67, ± 8.7) |
| Body mass index, mean (range, SD) | 25.3 (19-34, ± 3.1) |
| Real MELD score, mean (range, SD) | 15.6 (7-33, ± 6.5) |
| Correct MELD score, mean (range, SD) | 26.7 (11-39, ± 7.2) |
| UNOS status | |
| 2A | 5 (17.5) |
| 2B | 15 (53.6) |
| 3 | 8 (28.6) |
| Time waiting list (d), mean (range, SD) | 452 (37-1962, ± 393.5) |
| Associated hepatocellular carcinoma | 19 (69.7) |
| Meeting Milan criteria | 13 (46.4) |
| Meeting UCSF criteria | 6 (21.4) |
| HBsAg status | |
| Positive | 23 (82.1) |
| Negative | 5 (17.9) |
| HBV DNA positive at LT | 12 (52.1) |
| HCV co-infection | 4 (14.3) |
| HDV co-infection | 0 |
UCSF: University of California, San Francisco; LT: Liver transplantation; HCV: Hepatitis C virus; HDV: Hepatitis D virus; MELD: Model for end-stage disease.